Please visit our MS learning channel on Youtube, which provides hundreds of topics from our education programs, that were video-recorded and archived here: www.youtube.com/msviewsandnews

joomla ecommerce template -- Scroll left side of this blog for needed resources. Also, use our 'search by topic' tool, to find specific information.

Disclaimer: 'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider. The intent of this blog is to provide information on various medical conditions, medications, treatments, and procedures for your personal knowledge and to keep you informed of current health-related issues. It is not intended to be complete or exhaustive, nor is it a substitute for the advice of your physician. Should you or your family members have any specific medical problem, seek medical care promptly.

=================

CHAMPIONS TACKLING MS - AWARDS Dinner, Honoring Aaron Boster, MD and Jon e. Glaser, DDS - now open for registration. Visit www.events.msvn.org

Thursday, April 20, 2017

Converting the Hemp plant to CBD oil for Wellness


                                                                  
  



Green Roads Wellness is committed to improving the lives of its patients and their families.  Standing behind the purpose of inspiring hope and restoring happiness, Green Roads Wellness produces the highest quality, pharmacist formulated CBD products to pave the way for a healthier, happier life.


There’s Always an Alternative.



1500MG- CBD OIL
1500MG medical tincture is a purely sublingual oil with a full spectrum hemp oil base, pharmaceutical-grade cannabidiol, and reinfused with terpenes. The combination of pure CBD isolate, full spectrum CBD oil, and terpenoids create a powerful Entourage Effect where the cannabinoids work together synergistically producing a more physical effect in the body. This is our most powerful formula and the source of countless positive testimonials among users and their family members.      (Other MG Dosages are available as well)

300MG - PAIN CREAM 
Our natural pain cream offers a soothing and effective delivery system. A hemp based topical formulated with a pharmaceutical grade cream base, Menthol, Essential Oils and 300MG of cannabidiol making this the most powerful CBD pain topical on the market.

150MG - SKIN RELIEF
Cannabis is a known anti-inflammatory, with antioxidant and anti-aging properties. Our natural skin relief topical offers a soothing and effective delivery system.  It is a proprietary hemp based topical formulated with grapeseed oil, vitamin E oil, essential oils, aloe vera, and cannabidiol.  This product is designed for direct application to affected areas on the skin.

To further review or to request information, click here




'MS Views and News' DOES NOT endorse any products or services found on this blog. It is up to you to seek advice from your healthcare provider.

.
MS Views and News is MAKING an IMPACT on those affected by Multiple Sclerosis


Genentech to Present New Data at AAN Reinforcing Efficacy And Safety of Newly FDA Approved Ocrevus (Ocrelizumab) in Two Types of Multiple Sclerosis


                                                                  
  
Click here to receive MS news via e-mail


Data presentations will include platform sessions and posters across relapsing multiple sclerosis and primary progressive multiple sclerosis

The press release is below and can be found HERE.    
South San Francisco, CA -- April 18, 2017 --
Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), announced today that new data on OCREVUS™ (ocrelizumab) in people with relapsing forms of multiple sclerosis (RMS) and primary progressive MS (PPMS) will be presented during the 69th American Academy of Neurology (AAN) Annual Meeting from April 22-28 in Boston, Massachusetts.
Data presented across three platform sessions will describe the rapid benefit of OCREVUS in RMS patients in the first eight weeks of treatment and its effect on fatigue in PPMS patients. Efficacy and safety data from the open-label extension study will also be presented, as well as the effect of OCREVUS on active disease and progression in PPMS.
“OCREVUS is the only disease-modifying therapy approved by the FDA for people with primary progressive MS and offers people with relapsing MS a new treatment option with a favorable benefit-risk profile,” said Sandra Horning, M.D., chief medical officer and head of Global Product Development. “The data being presented at AAN will demonstrate how rapidly OCREVUS controls disease activity and reduces brain MRI lesions in people with early RMS, both of which are important goals of treatment.”
Leading investigators will present the following oral and poster presentations:
Abstract Title
Abstract Number (type), Presentation Date, Time
Rapid Onset of Ocrelizumab Suppression of Brain MRI Activity in Relapsing-Remitting Multiple Sclerosis
S12.008 (oral), Monday, April 24, 2:24 p.m. EDT
Multimodal Evoked Potentials in Primary Progressive MS: A Potential Biomarker for Prognosis and Course
P2.350 (poster), Monday, April 24, 5:00 p.m. EDT
Rapidity of Onset of Ocrelizumab Clinical Efficacy in Relapsing Multiple Sclerosis
S31.002 (oral), Wednesday, April 26, 1:12 p.m. EDT
Preliminary Results of the OPERA I and OPERA II Open-Label Extension Study
S31.004 (oral), Wednesday, April 26, 1:36 p.m. EDT
The Association Between Confirmed Disability Progression and Patient-reported Fatigue in PPMS Patients in the ORATORIO study
S33.006 (oral), Wednesday, April 26, 4:30 p.m. EDT
No Evidence of Disease Activity on Ocrelizumab Treatment in Patients With Early Relapsing Multiple Sclerosis: Pooled Analysis of the Phase III OPERA Studies
P4.391 (poster), Wednesday, April 26, 5:30 p.m. EDT
Evaluation of No Evidence of Progression or Active Disease (NEPAD) in Patients with Primary Progressive Multiple Sclerosis in the ORATORIO Trial
P4.384 (poster), Wednesday, April 26, 5:30 p.m. EDT
Safety of Ocrelizumab in Multiple Sclerosis: Updated Analysis in Patients with Relapsing and Primary Progressive Multiple Sclerosis
P5.407 (poster), Thursday, April 27, 5:30 p.m. EDT
Effects of Ocrelizumab on Neurofilament Light Chain and Other Biomarkers of Neuroinflammation and Neurodegeneration in MS: OBOE Study Design
P6.337 (poster), Friday, April 28, 4:00 p.m. EDT
Efficacy of Ocrelizumab on Brain MRI Outcomes in Patients with Early Relapsing Multiple Sclerosis: Pooled Analysis of the OPERA Studies
P6.338 (poster), Friday, April 28, 4:00 p.m. EDT
Advanced Myelin-related MRI Measures in Relapsing Multiple Sclerosis Patients Treated with Ocrelizumab or Interferon Beta-1a Over 96 Weeks
P6.371 (poster), Friday, April 28, 4:00 p.m. EDT
Full session details and data presentation listings for the 2017 AAN Annual Meeting can be found at the meeting website: https://www.aan.com/conferences/2017-annual-meeting/ .
OCREVUS received approval from the U.S. Food and Drug Administration (FDA) on March 28, 2017 for the treatment of adult patients with relapsing or primary progressive forms of MS.
Follow Genentech on Twitter via @Genentech and keep up to date with AAN 2017 Annual Meeting news and updates by using the hashtag #AANAM.
About OCREVUS ™ (ocrelizumab)
OCREVUS is a humanized monoclonal antibody designed to selectively target CD20-positive B cells, a specific type of immune cell thought to be a key contributor to myelin (nerve cell insulation and support) and axonal (nerve cell) damage. This nerve cell damage can lead to disability in people with MS. Based on preclinical studies, OCREVUS binds to CD20 cell surface proteins expressed on certain B cells, but not on stem cells or plasma cells, and therefore important functions of the immune system may be preserved.
OCREVUS is administered by intravenous infusion every six months. The first dose is given as two 300 mg infusions given two weeks apart. Subsequent doses are given as single 600 mg infusions.
OCREVUS U.S. Indication
OCREVUS is a prescription medicine used to treat adults with relapsing or primary progressive forms of multiple sclerosis.
It is not known if OCREVUS is safe or effective in children.
Important Safety Information
Who should not receive OCREVUS?
Do not receive OCREVUS if you are a patient that has an active hepatitis B virus (HBV) infection. Do not receive OCREVUS if you are a patient that has had a life threatening allergic reaction to OCREVUS. Patients should tell their healthcare provider if they have had an allergic reaction to OCREVUS or any of its ingredients in the past.
What is the most important information about OCREVUS?

OCREVUS can cause serious side effects, including:
·       Infusion Reaction: OCREVUS can cause infusion reactions that can be serious and require a patient to be hospitalized. A patient will be monitored during the infusion and for at least 1 hour after each infusion of OCREVUS for signs and symptoms of an infusion reaction. Patients should tell their healthcare provider or nurse if they get any of these symptoms: itchy skin, rash, hives, tiredness, coughing or wheezing, trouble breathing, throat irritation or pain, feeling faint, fever, redness on the face (flushing), nausea, headache, swelling of the throat, dizziness, shortness of breath, fatigue, fast heart beat.
These infusion reactions can happen for up to 24 hours after the infusion. It is important that patients call their healthcare provider right away if they get any of the signs or symptoms listed above after each infusion. If a patient gets infusion reactions, the healthcare provider may need to stop or slow down the rate of the infusion.
·       Infection: OCREVUS increases a patient’s risk of getting upper respiratory tract infections, lower respiratory tract infections, skin infections, and herpes infections. Patients should tell their healthcare provider if they have an infection or have any of the following signs of infection including fever, chills, a cough that does not go away, or signs of herpes (such as cold sores, shingles, or genital sores). These signs can happen during treatment or after a patient has received their last dose of OCREVUS. If a patient has an active infection, their healthcare provider should delay treatment with OCREVUS until the infection is gone.
·       Progressive Multifocal Leukoencephalopathy (PML): Although no cases have been seen with OCREVUS treatment, PML may happen with OCREVUS. PML is a rare brain infection that usually leads to death or severe disability. Patients should tell their healthcare provider right away if they have any new or worsening neurologic signs or symptoms. These may include problems with thinking, balance, eyesight, weakness on one side of the body, strength, or using arms or legs.
·       Hepatitis B virus (HBV) reactivation: Before starting treatment with OCREVUS, a patient’s healthcare provider will do blood tests to check for hepatitis B viral infection. If a patient has ever had hepatitis B virus infection, the hepatitis B virus may become active again during or after treatment with OCREVUS. Hepatitis B virus becoming active again (called reactivation) may cause serious liver problems including liver failure or death. A healthcare provider will monitor a patient if they are at risk for hepatitis B virus reactivation during treatment and after they stop receiving OCREVUS.
·       Weakened immune system: OCREVUS taken before or after other medicines that weaken the immune system could increase a patient’s risk of getting infections.
Before receiving OCREVUS, patients should tell their healthcare provider about all of their medical conditions, including if they:
·       have ever taken, take, or plan to take medicines that affect the immune system, or other treatments for MS.
·       have ever had hepatitis B or are a carrier of the hepatitis B virus.
·       have had a recent vaccination or are scheduled to receive any vaccinations. A patient should receive any required vaccines at least 6 weeks before they start treatment with OCREVUS. A patient should not receive certain vaccines (called ‘live’ or ‘live attenuated’ vaccines) while being treated with OCREVUS and until their healthcare provider tells them that their immune system is no longer weakened.
·       are pregnant, think that they might be pregnant, or plan to become pregnant. It is not known if OCREVUS will harm an unborn baby. Patients should use birth control (contraception) during treatment with OCREVUS and for 6 months after the last infusion of OCREVUS.
·       are breastfeeding or plan to breastfeed. It is not known if OCREVUS passes into the breast milk. Patients should talk to their healthcare provider about the best way to feed their baby if the patient takes OCREVUS.
What are possible side effects of OCREVUS?
OCREVUS may cause serious side effects, including:
·       Risk of cancers (malignancies) including breast cancer. Patients should follow their healthcare provider’s recommendations about standard screening guidelines for breast cancer.
Most common side effects include infusion reactions and infections.
These are not all the possible side effects of OCREVUS.
Patients should call their doctor for medical advice about side effects. 
Patients may report side effects to the FDA at (800) FDA-1088 or
Patients may also report side effects to Genentech at (888) 835-2555.
For additional safety information, please see the OCREVUS full Prescribing Information and Medication Guide. 
For more information, go to http://www.OCREVUS.com or call 1-844-627-3887.

About Genentech in neuroscience
Neuroscience is a major focus of research and development at Genentech and Roche. The company’s goal is to develop treatment options based on the biology of the nervous system to help improve the lives of people with chronic and potentially devastating diseases. Roche has more than a dozen investigational medicines in clinical development for diseases that include multiple sclerosis, Alzheimer’s disease, spinal muscular atrophy, Parkinson’s disease and autism.
About Genentech
Founded 41 years ago, Genentech is a leading biotechnology company that discovers, develops, manufactures and commercializes medicines to treat patients with serious or life-threatening medical conditions. The company, a member of the Roche Group, has headquarters in South San Francisco, California. For additional information about the company, please visit http://www.gene.com.
All trademarks used or mentioned in this release are protected by law.
 ###




MS Views and News is MAKING an IMPACT on those affected by Multiple Sclerosis

No Evidence of Disease Activity Achieved in Multiple Sclerosis with Dimethyl Fumarate


                                                                  
  
Click here to receive MS news via e-mail


Post hoc data analysis of the DEFINE and CONFIRM trials showed that a higher percentage of patients with relapsing-remitting multiple sclerosis (RRMS) achieved no evidence of disease activity (NEDA) with delayed-release dimethyl fumarate (DMF) compared with placebo. The results were published in the European Journal of Neurology.1
NEDA is a relatively new composite outcome that is being used more often to measure therapeutic response in multiple sclerosis. NEDA is comprised of 3 factors: no clinical relapse, no disability progression measured by the Expanded Disability Status Scale (EDSS) for 12 weeks, and no evidence of disease activity on magnetic resonance imaging (MRI).





MS Views and News
Providing educational information, resources and services for those affected by MS, globally
MS Views and News is MAKING an IMPACT on those affected by Multiple Sclerosis

Monday, April 17, 2017

3D Laboratory Cell Growth System Should Speed Up MS Remyelination Research


                                                                  
  
Click here to receive MS news via e-mail

A physical scaffold that allows lab-grown brain cells to grow in a three-dimensional manner is giving scientists a whole new way of studying the regeneration of myelin, nerve coatings whose damage is at the heart of multiple sclerosis.
The scaffold is allowing researchers to test large numbers of compounds for their capacity to trigger remyelination. This could lead to an acceleration of research into regenerative drugs for MS

3D Laboratory Cell Growth System Should Speed Up MS Remyelination Research


“The aligned Mimetix scaffold fibres from AMSBIO have been an invaluable tool, allowing us to answer fundamental questions regarding how oligodendrocytes form central nervous system (CNS) myelin sheaths,” Marie Bechler, a senior researcher in the Constant laboratory at the MRC Centre for Regenerative Medicine in Scotland, said in a press release.
The three-dimensional orientation of cells in the central nervous system determines how cells grow and behave. Earlier methods of growing brain cells in a lab dish have been unable to mirror everything that goes on in a living human.
MRC Centre researchers are using the three-dimensional fiber technology that AMSBIO developed to study oligodendrocyte cells and myelin regeneration. Oligodendrocytes are cells that wrap their appendages around nerve cells to form myelin.

MS Views and News is MAKING an IMPACT on those affected by Multiple Sclerosis

Firefighter with Relapsing MS on Ocrevus: ‘I Have Really Good Days and I Have Bad Days’


                                                                  
  
Click here to receive MS news via e-mail


Texas firefighter Wayne Donovan is among the estimated 250,000 to 350,000 Americans with multiple sclerosis (MS). He enrolled in a clinical trial testing Ocrevus (ocrelizumab), which the  U.S. Food and Drug Administration recently approved as the first therapy for both relapsing and primary progressive forms of MS.
Donovan was diagnosed in 2011 at the age of 39, after he started feeling numbness in his hand and foot and saw a orthopedist, thinking he might have pinched a nerve. The orthopedist, however, recognized that it could be something more serious and referred him to neurologist Dr. Edward Fox at Central Texas Neurology Consultants in suburban Austin.
Fox diagnosed Donovan with relapsing MS — an unpredictable form of the disease.
Texas firefighter and MS patient Wayne Donovan. (Photo credit: Ocrevus)
“By the time I saw Dr. Fox, about three-quarters of my body was either numb or tingling, or had pins and needles,” Donovan said in a news release. “As a firefighter, I have to be strong and present in tough situation. I didn’t know what this meant for me and my family.”
The ultimate cause of MS is damage to myelin, nerve fibers and neurons in the brain and spinal cord, which together make up the central nervous system, causing inflammation and other debilitating symptoms. Relapsing MS is characterized by episodes of new or worsening signs or relapses, followed by periods of recovery.
Ocrevus targets immune B-cells that express a protein called CD20 on their surface, giving the drug an immunosuppressive function. The medication, developed by Genentech — a unit of the Roche Group — aims to reduce the immune system’s attacks on myelinated neurons, the main trigger of the disease.
Fox knew about a clinical trial that was investigating Ocrevus and suggested that Donovan enroll. After considering the pros and cons, Donovan enrolled and started receiving Ocrevus soon after. In the trial, the drug was administered every six months as an intravenous infusion.

MS Views and News is MAKING an IMPACT on those affected by Multiple Sclerosis